SITC 2023 Poster 196

Tumor-associated SIRPα Expression Evaluation in Melanoma PDX Models via IHC for Potential ICI-predictive Applications

Xiaolong Tu¹, Likun Zhang¹, Wenjuan Zhou¹, Hongjiang Yu¹, Cheng Jiang¹, Henry Li² and Annie Xiaoyu An¹

¹Crown Bioscience, Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, USA
²Hanx Pharmaceuticals, Inc., 3561 Voyager Ct., Oceanside, CA 92054 , USA

Immune checkpoint inhibition (ICI) therapy, particularly PD-1/PD-L1 blockade, has heralded a new era in cancer treatment. However, with a response rate of only about 26%, the quest for precise biomarkers to determine beneficiaries is paramount. Enter SIRPα, a promising immune regulatory target that showcases "don't eat me" signaling. Our exploration dives deep into the potential of tumor-associated SIRPα as a predictive biomarker, using a robust IHC assay on melanoma patient-derived xenograft (PDX) samples, mirroring real-life tumor characteristics.

Download this Poster to Discover:

• SIRPα's role in predicting melanoma treatment outcomes.
  
  
• Our cutting-edge IHC assay approach on melanoma PDX models.
  
  
• Correlation findings between SIRPα expression and IHC scores aligned with TCGA data.

Download the Poster Now!